Saturday 17 October 2026
Export GTBP’s income statement to Excel — free account
GT Biopharma, Inc.
GTBP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.
7.03
0.33
−4.48%
Follow GTBP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 102.03% | (1,122.83%) | (1,674.31%) | (1,205.42%) |
+8 more TTM periods Free account |
|
| (176.27%) | (585.46%) | (558.42%) | (554.30%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (1,746.37%) | |
Return on Tangible Assets |
(318.86%) | (488.68%) | (595.28%) | (1,023.60%) | |
Free Cash Flow per Share |
(9.29) | (10.88) | (58.57) | (72.09) | |
Free Cash Flow |
(14.43) | (13.18) | (12.91) | (11.36) | |
| Other line items | |||||
Cash ROIC |
(167.30%) | (79.41%) | (101.75%) | (202.12%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(47.49) | (27.11) | — | — | |
Operating CF/Net income |
1.27 | 0.36 | 0.37 | 0.37 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(9.29) | (10.88) | (58.57) | (72.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates